Phase 2a Dose-Ranging Study to Evaluate Safety and Effectiveness of AA4500 in Treatment of Dupuytren's Disease Nodules

NCT02193828 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

76

Enrollment

INDUSTRY

Sponsor class

Conditions

Dupuytren's Disease

Interventions

BIOLOGICAL: Collagenase clostridium histolyticum
BIOLOGICAL: Placebo

Sponsor

Endo Pharmaceuticals